KALQUEST® Powder for Oral Suspension 5gsachet

Quốc gia: Malaysia

Ngôn ngữ: Tiếng Anh

Nguồn: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Thành phần hoạt chất:

CALCIUM POLYSTYRENE SULFONATE

Sẵn có từ:

AVERROES PHARMACEUTICALS SDN. BHD.

INN (Tên quốc tế):

CALCIUM POLYSTYRENE SULFONATE

Các đơn vị trong gói:

30 Sachets

Sản xuất bởi:

PT.NOVELL PHARMACEUTICAL LABORATORIES

Tờ rơi thông tin

KALQUEST
®
POWDER FOR ORAL SUSPENSION 5G/SACHET
Calcium Polystyrene Sulfonate (5 g)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What Kalquest® is used for
2.
How Kalquest® works
3.
Before you use Kalquest®
4.
How to use Kalquest®
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of Kalquest®
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT KALQUEST®
IS USED FOR
Kalquest®
contains
a
medicine
called
Calcium
polystyrene
sulfonate.
This
belongs to a group of medicines called
‘ion exchange resins’. Kalquest® is used
to treat hyperkalaemia, a condition when
there is too much potassium in your blood
due to renal failure.
HOW KALQUEST®
WORKS
Kalquest® works by removing this extra
potassium to bring your levels back to
normal.
BEFORE YOU USE KALQUEST®
-
_When you must not use it _
Do not use Kalquest® if you:
•
Are allergic to calcium polystyrene
sulfonate
or
any
of
the
other
ingredients in this medicine.
•
Have low level of potassium in your
blood
•
Have medical problems that result in
high level of calcium such as thyroid
problem
•
Have partially or completely blocked
gut
•
Are taking a sweetener called sorbitol.
_ _
_Pregnancy and lactation _
Do
not
take
Kalquest®
if
you
are
pregnant, trying to get pregnant or think
you may be pregnant.
Do not take Kalquest® if you are breast-
feeding. Ask your doctor or pharmacist
for advice before taking any medicine.
-
_Before you start use it _
Check
with
your
doctor,
nurse
or
pharmacist before using Kalquest®. If
it is for your baby, tell them if your
baby was premature, had a low birth-
weight or has a reduced gut movement.
-
_Taking other medicines _
Tell your doctor if you are taking any
other medicines, including any that you
buy
without
a
prescription
from
a
pharmacy, supermarket or health food
shop.
In particular, it is not recommended to
take
Kalquest®
together
with
medications used as a laxative, either
by oral or rectal as it may cause serious

Đặc tính sản phẩm

KALQUEST
® POWDER FOR ORAL SUSPENSION 5 G/SACHET
CALCIUM POLYSTYRENE SULFONATE 5.0 G
PRODUCT DESCRIPTION
Before reconstitution: fine powder, cream colour, mocha aroma, and
slightly sweet
After reconstitution: suspension, cream colour, mocha aroma, and
slightly sweet
PHARMACODYNAMICS
Kalquest® is a cation exchange resin which releases calcium in the
intestines and binds
potassium. This reduces the absorption and metabolic availability of
potassium.
PHARMACOKINETICS
Not applicable as this product is not absorbed.
INDICATION
Kalquest® is used to treat hyperkalaemia resulting from acute or
chronic renal failure.
RECOMMENDED DOSAGE
15 - 30g daily in 2 -3 divided doses. Each dose should be suspended in
30 - 50ml of water and
administered orally.
The dosage recommendations are a guide only; the precise requirements
should be decided on
the basis of regular serum electrolyte determinations.
ROUTE OF ADMINISTRATION
Oral
CONTRAINDICATIONS

In patients with plasma potassium levels below 5 mmol/litre

Conditions associated with hypercalcaemia (e.g. hyperparathyroidism,
multiple
myeloma, sarcoidosis or metastatic carcinoma)

History of hypersensitivity to polystyrene sulfonate resins

Obstructive bowel disease

Kalquest® should not be administered orally to neonate

Hypersensitivity to the active substance or to any of the excipients
WARNING AND PRECAUTIONS
_Sorbitol: _
Gastrointestinal stenosis, intestinal ischemia and its complications
(necrosis and
perforation) may occur in patients treated with polystyrene sulfonate,
especially in patients
using sorbitol. Therefore concomitant use of Sorbitol with calcium
polystyrene sulfonate is not
recommended.
_Hypokalaemia: _
The possibility of severe potassium depletion should be considered and
adequate clinical and biochemical control is essential during
treatment, especially in patients
on digitalis. Administration of the resin should be stopped when the
serum potassium falls to
5 mmol/litre.
_Other electrolyte disturbances: _
Like all cation-exchange resins,